Axsome Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AXSM and other ETFs, options, and stocks.

About AXSM

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. 

CEO
Herriott Tabuteau
CEOHerriott Tabuteau
Employees
925
Employees925
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2012
Founded2012
Employees
925
Employees925

AXSM Key Statistics

Market cap
7.31B
Market cap7.31B
Price-Earnings ratio
-45.61
Price-Earnings ratio-45.61
Dividend yield
—
Dividend yield—
Average volume
1.31M
Average volume1.31M
High today
$145.50
High today$145.50
Low today
$136.79
Low today$136.79
Open price
$136.79
Open price$136.79
Volume
1.68M
Volume1.68M
52 Week high
$260.19
52 Week high$260.19
52 Week low
$123.00
52 Week low$123.00

Stock Snapshot

With a market cap of 7.31B, Axsome Therapeutics(AXSM) trades at $139.61. The stock has a price-to-earnings ratio of -45.61.

During the trading session on 2026-11-04, Axsome Therapeutics(AXSM) shares reached a daily high of $145.50 and a low of $136.79. At a current price of $139.61, the stock is +2.1% higher than the low and still -4.0% under the high.

Trading activity shows a volume of 1.68M, compared to an average daily volume of 1.31M.

Over the past 52 weeks, Axsome Therapeutics(AXSM) stock has traded between a high of $260.19 and a low of $123.00.

Over the past 52 weeks, Axsome Therapeutics(AXSM) stock has traded between a high of $260.19 and a low of $123.00.

AXSM News

Simply Wall St 6h
Axsome Therapeutics Q3 Earnings Narrow Losses As Revenue Jumps - Simply Wall St

...

Axsome Therapeutics Q3 Earnings Narrow Losses As Revenue Jumps - Simply Wall St
Simply Wall St 1d
Reduced Losses Could Change The Case For Axsome Therapeutics

Axsome Therapeutics reported third quarter 2026 revenue of US$259.69 million and a net loss of US$12.88 million, with basic and diluted loss per share of US$0.2...

Reduced Losses Could Change The Case For Axsome Therapeutics
Benzinga 2d
Axsome Therapeutics Q3 2026 Earnings Call Transcript - Benzinga

...

Axsome Therapeutics Q3 2026 Earnings Call Transcript - Benzinga

Analyst ratings

96%

of 23 ratings
Buy
95.7%
Hold
4.3%
Sell
0%

More AXSM News

TipRanks 2d
Axsome Therapeutics Reports Strong Third-Quarter Revenue Growth

Axsome Therapeutics ( (AXSM) ) has shared an update. Axsome Therapeutics is a biopharmaceutical company focused on central nervous system disorders, with AUVEL...

People also own

Based on the portfolios of people who own AXSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.